Triglyceride-glucose index as a suitable non-insulin-based insulin resistance marker to predict cardiovascular events in patients undergoing complex coronary artery intervention: a large-scale cohort study

Table 2 the TyG index in relation to CV events and MACEs

	Events (%)	Univariable models		Multivariable models*
	Events (%)	HR (95%CI)	P value	HR (95%CI)	P value
CV events^a
Per-unit increase in TyG index	324 (3.5)	1.34 (1.11–1.61)	0.002	1.42 (1.13–1.77)	0.002
TyG index tertiles
T1	87 (2.9)	Reference	–	Reference	–
T2	116 (3.8)	1.34 (1.02–1.77)	0.038	1.39 (1.05–1.85)	0.023
T3	121 (4.0)	1.40 (1.06–1.84)	0.018	1.45 (1.06–1.99)	0.021
MACEs^b
Per-unit increase in TyG index	269 (2.9)	1.36 (1.11–1.67)	0.003	1.39 (1.09–1.78)	0.008
TyG index tertiles
T1	68 (2.2)	Reference	–	Reference	–
T2	101 (3.3)	1.50 (1.10–2.04)	0.010	1.54 (1.12–2.11)	0.008
T3	100 (3.3)	1.48 (1.09–2.01)	0.013	1.48 (1.04–2.11)	0.027

CV cardiovascular, TyG triglyceride-glucose, TG triglyceride, HDL-C high-density lipoprotein cholesterol, METS-IR metabolic score for insulin resistance, BMI body mass index, CCS chronic coronary syndrome, ACS acute coronary syndrome, CAD coronary artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, PAD peripheral artery disease, CKD chronic kidney disease, SBP systolic blood pressure, DBP diastolic blood pressure, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, FPG fasting plasma glucose, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, hsCRP high sensitivity C-reactive protein, SYNTAX synergy between PCI with taxus and cardiac surgery, CTO chronic total occlusion, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker
^*Models adjusted for age, male sex, BMI, ACS presentations, previous MI, previous PCI, previous CABG, hypertension, diabetes, previous stroke, current smoker, LVEF, eGFR, TC, LDL-C, hsCRP, SYNTAX score, total stent number, aspirin use and statins use
^aCV events were defined as a composite of CV death, nonfatal MI and nonfatal stroke
^bMACEs were defined as a composite of CV death and nonfatal MI

ISSN: 1475-2840